Aurinia Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Aurinia Pharmaceuticals

15/02/2024 14:32

* Aurinia Pharmaceuticals Inc  AUPH.OQ  reported a quarterly
adjusted loss of 19 cents​​ per share for the quarter ended in
December, lower than the same quarter last year, when the
company reported EPS of -18 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 16 cents per
share. Wall Street expected results to range from -24 cents
to -14 cents per share.
    * Revenue rose 58.6% to $45.10 million from a year ago;
analysts
expected $44.33 million. 
    * Aurinia Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 19 cents​.
    * The company reported a quarterly loss of $26.88 million.
    * Aurinia Pharmaceuticals Inc shares had fallen by 11.3%
this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is $13.00 

This summary was machine generated from LSEG data February 15 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.16          -0.19          Missed
 Sep. 30 2023      -0.17          -0.09          Beat
 Jun. 30 2023      -0.18          -0.08          Beat
 Mar. 31 2023      -0.22          -0.18          Beat